GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DMS Imaging SA (XBRU:ALIMG) » Definitions » EV-to-EBIT

DMS Imaging (XBRU:ALIMG) EV-to-EBIT : -174.51 (As of May. 04, 2024)


View and export this data going back to 2016. Start your Free Trial

What is DMS Imaging EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DMS Imaging's Enterprise Value is €48.51 Mil. DMS Imaging's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.28 Mil. Therefore, DMS Imaging's EV-to-EBIT for today is -174.51.

The historical rank and industry rank for DMS Imaging's EV-to-EBIT or its related term are showing as below:

XBRU:ALIMG' s EV-to-EBIT Range Over the Past 10 Years
Min: -383.43   Med: -5.59   Max: 1.64
Current: -174.51

During the past 12 years, the highest EV-to-EBIT of DMS Imaging was 1.64. The lowest was -383.43. And the median was -5.59.

XBRU:ALIMG's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs XBRU:ALIMG: -174.51

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. DMS Imaging's Enterprise Value for the quarter that ended in Dec. 2023 was €47.77 Mil. DMS Imaging's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.28 Mil. DMS Imaging's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.58%.


DMS Imaging EV-to-EBIT Historical Data

The historical data trend for DMS Imaging's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMS Imaging EV-to-EBIT Chart

DMS Imaging Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.52 -8.50 -361.90 -17.38 -171.83

DMS Imaging Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -361.90 - -17.38 - -171.83

Competitive Comparison of DMS Imaging's EV-to-EBIT

For the Biotechnology subindustry, DMS Imaging's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMS Imaging's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DMS Imaging's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DMS Imaging's EV-to-EBIT falls into.



DMS Imaging EV-to-EBIT Calculation

DMS Imaging's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=48.513/-0.278
=-174.51

DMS Imaging's current Enterprise Value is €48.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DMS Imaging's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DMS Imaging  (XBRU:ALIMG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

DMS Imaging's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-0.278/47.767835
=-0.58 %

DMS Imaging's Enterprise Value for the quarter that ended in Dec. 2023 was €47.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DMS Imaging's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DMS Imaging EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of DMS Imaging's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


DMS Imaging (XBRU:ALIMG) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

DMS Imaging (XBRU:ALIMG) Headlines

No Headlines